肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2014年
1期
54-58
,共5页
姚远%易平勇%刘晰宇%周芳%孙中义%欧阳周%贺军侨%黄利军
姚遠%易平勇%劉晰宇%週芳%孫中義%歐暘週%賀軍僑%黃利軍
요원%역평용%류석우%주방%손중의%구양주%하군교%황리군
套细胞淋巴瘤%自体外周血造血干细胞移植%常规化疗
套細胞淋巴瘤%自體外週血造血榦細胞移植%常規化療
투세포림파류%자체외주혈조혈간세포이식%상규화료
Mantle cell lymphoma%Autologous stem cell transplantation%Conventional chemotherapy
目的：探讨自体外周血造血干细胞移植（ASCT）联合大剂量化疗治疗套细胞淋巴瘤的临床疗效及安全性。方法总结2000年1月~2011年1月进行的自体外周造血干细胞移植联合大剂量化疗的28例套细胞淋巴瘤患者（移植组）的临床资料，并与同期28例接受常规治疗的套细胞淋巴瘤患者（常规化疗组）进行比较。结果移植组 CR为67.9％，PR 为32.1％，常规化疗组 CR 为57.1％，PR 为42.9％，两组总有效率比较，差异无统计学意义（P>0.05）；移植组5年 OS（65％）显著高于常规化疗组（42％），5年 DFS（53％）亦高于常规化疗组（34％），差异均有统计学意义（P<0.05）。移植组Ⅳ度骨髓抑制的发生率（100％）明显高于常规化疗组（17.9％），差异有统计学意义（P<0.05）。结论ASCT 支持下大剂量化疗治疗套细胞淋巴瘤的临床疗效好于常规化疗，且安全性较高。
目的：探討自體外週血造血榦細胞移植（ASCT）聯閤大劑量化療治療套細胞淋巴瘤的臨床療效及安全性。方法總結2000年1月~2011年1月進行的自體外週造血榦細胞移植聯閤大劑量化療的28例套細胞淋巴瘤患者（移植組）的臨床資料，併與同期28例接受常規治療的套細胞淋巴瘤患者（常規化療組）進行比較。結果移植組 CR為67.9％，PR 為32.1％，常規化療組 CR 為57.1％，PR 為42.9％，兩組總有效率比較，差異無統計學意義（P>0.05）；移植組5年 OS（65％）顯著高于常規化療組（42％），5年 DFS（53％）亦高于常規化療組（34％），差異均有統計學意義（P<0.05）。移植組Ⅳ度骨髓抑製的髮生率（100％）明顯高于常規化療組（17.9％），差異有統計學意義（P<0.05）。結論ASCT 支持下大劑量化療治療套細胞淋巴瘤的臨床療效好于常規化療，且安全性較高。
목적：탐토자체외주혈조혈간세포이식（ASCT）연합대제양화료치료투세포림파류적림상료효급안전성。방법총결2000년1월~2011년1월진행적자체외주조혈간세포이식연합대제양화료적28례투세포림파류환자（이식조）적림상자료，병여동기28례접수상규치료적투세포림파류환자（상규화료조）진행비교。결과이식조 CR위67.9％，PR 위32.1％，상규화료조 CR 위57.1％，PR 위42.9％，량조총유효솔비교，차이무통계학의의（P>0.05）；이식조5년 OS（65％）현저고우상규화료조（42％），5년 DFS（53％）역고우상규화료조（34％），차이균유통계학의의（P<0.05）。이식조Ⅳ도골수억제적발생솔（100％）명현고우상규화료조（17.9％），차이유통계학의의（P<0.05）。결론ASCT 지지하대제양화료치료투세포림파류적림상료효호우상규화료，차안전성교고。
Objective To investigate the clinical efficacy and safety of autologous peripheral blood stem cells transplantation (ASCT) plus intensive chemotherapy in the treatment of mantle cell lymphoma (MCL). Methods The clinical data of 28 cases of MCL patients who were treated with first-line intensive chemotherapy followed by ASCT were collected and compared with that of 28 cases of MCL patients who were treated with conventional chemotherapy between January 2000 and January 2011. All patients had received EPOCH for 6-8 cycles, and autologous stem cell transplantation group were administrated with intensive chemotherapy followed by ASCT after complete remission or partial remission. Results The CR and PR were respectively 67.9% and 32.1% in ASCT group, and were 57.1% and 42.9% in the conventional chemotherapy group. There was no statistical significance between two groups (all P>0.05). But the 5-year OS of ASCT group was significantly higher than that of the conventional chemotherapy group (65% vs.42%), as well as the 5-year DFS (53% vs.34%), (all P<0.05). Only the incidence rate of Ⅳ° myelosuppression in ASCT group was higher than that in conventional chemotherapy group (100% vs.17.9%) (P<0.05). Conclusion The intensive chemotherapy fol-lowed by ASCT had better clinical efficacy than conventional chemotherapy in the treatment of MCL, with relatively higher safety.
